FilingReader Intelligence
Dawnrays Pharmaceutical profit plunges 79% despite revenue growth
August 22, 2025 at 03:09 PM UTC•By FilingReader AI
Dawnrays Pharmaceutical reported profit of RMB101.7m for the six months ended June 30, down 79.3% from RMB491.6m despite 9.2% revenue growth to RMB630.4m.
The decline was attributed to production capacity constraints and centralized procurement price drops, which cut gross profit margin by 8.7 percentage points. The company declared an interim dividend of HK$0.015 per share.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2348•Hong Kong Exchange
News Alerts
Get instant email alerts when Dawnrays Pharmaceutical Holdings publishes news
Free account required • Unsubscribe anytime